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The p53 gene is justly famous for its role as a tumor 
suppressor.  Loss of its function through structural 
alterations (inactivating mutations, deletions) occurs in 
roughly half of all human cancers, making it the most 
frequently mutated cancer-associated gene [1].  Yet p53 
does not function only to suppress cancer, as p53 
homologues are present in short-lived invertebrates such 
as worms (Caenorhabditis elegans) and flies 
(Drosophila melanogaster) that do not develop cancer 
[2].   p53 is known as the “guardian of the genome” and 
plays an important role in maintaining genomic 
integrity in response to cellular damage and stress [3].  
In response to DNA damage, p53 is activated and can 
induce cell cycle arrest of actively dividing cells, 
allowing time for repair of damage before re-entry into 
the cell cycle.  In other cases, where damage is 
extensive, p53 can induce apoptosis, preventing the 
propagation of damaged or dysfunctional cells.  It is 
likely that p53 protects flies and worms primarily by 
regulating apoptosis during embryogenesis.   Yet p53 
may play another role in flies as a longevity regulator, 
as illustrated by a paper by Helfand and colleagues in 
this issue [4].   
 
How does the capacity of p53 to regulate genomic 
integrity relate to its potential ability to regulate aging 
and longevity?  The first hints were obtained from 
genetically engineered mouse models that exhibited 
accelerated aging phenotypes and shortened longevity 
[5,6].  Such models frequently displayed evidence of an 
elevated p53 response, suggesting that enhanced p53 
activity might be partially responsible for these 
premature aging phenotypes.  More direct evidence for 
p53 involvement in longevity came from studies on two 
mouse models that expressed truncated mutant forms of  
 
 
 
                                                                        Review 
www.impactaging.com AGING, January 2009, Vol. 1. No 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Longevity regulation in flies: A role for p53
 
Lawrence A. Donehower 
 
Department of Molecular Virology and Microbiology, Department of Molecular and Cellular Biology, Baylor 
College of Medicine, Houston, TX  77030, USA 
 
Received: 12/29/08; accepted: 01/08/09; published on line: 01/10/09 
E‐mail: larryd@bcm.tmc.edu 
Copyright: © 2009 Donehower. This is an open‐access article distributed under the terms of the Creative Commons Attribution 
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source 
are credited 
 
p53 [7,8].   These mouse mutants, one generated by my 
laboratory, were resistant to cancer,  yet had significantly 
shortened longevity accompanied by a number of 
premature aging phenotypes.  We hypothesized that the 
truncated versions of p53 were causing aberrant 
regulation of resident wildtype p53, resulting in an 
augmented p53-mediated anti-proliferative response [9].  
This enhanced p53 response may inhibit functionality of 
stem and progenitor cell compartments, leading to some 
of the tissue atrophies and dysfunctions that 
accompanied the premature aging and shortened 
longevity phenotypes.  A number of laboratories have 
shown that increased activity of tumor suppressors such 
as p53 and p16
INK4a in stem cell compartments can lead 
to reduced stem cell self renewal, tissue reconstitution 
function, and early tissue atrophies [10-14].  It should 
be noted that transgenic mice with one or two copies of 
normally regulated p53, while showing cancer 
resistance, did not have altered longevity [15].   
However, if an additional copy of the intact tumor 
suppressor p19
ARF (which activates p53) was co-
expressed along with an additional copy of p53, aging 
could actually be delayed [16].  Thus, normally 
regulated, though augmented p53 function may be 
longevity enhancing, while aberrantly regulated, but 
enhanced p53 activity is detrimental to longevity 
(though both conditions inhibit cancer formation).   
 
The clear influence of p53 on mouse longevity, either 
lengthening or shortening it, led Helfand and colleagues 
to investigate the role of the Drosophila p53 
homologue, Dmp53, in longevity [17].   They found that 
null Dmp53 flies, while viable, are sickly and have a 
reduced lifespan, probably due to early negative effects 
on embryonic development.  However, when two domi- 
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inhibit wildtype p53 transactivation activity) were 
expressed in the neuronal cells of Drosophila, longevity 
was increased by up to 58%.  Even if the dominant 
negative (DN) p53 was expressed only in adult neurons, 
longevity extension of 26% could be achieved.  That 
this longevity effect was tissue-specific was shown by 
the fact that DN Dmp53 expression in muscle or fat 
body cells resulted in no longevity enhancement.   Thus, 
DN dmp53 mediated reduction of p53 activity in 
specific tissues could lead to delayed aging and 
extended longevity.    
 
Insights into the mechanisms of this neuronal Dmp53 
effect were provided by the finding that calorie 
restriction (CR) of the neuronal DN Dmp53 flies does 
not provide any additional lifespan extension beyond 
that observed in non-restricted DN Dmp53 flies [17].  
Calorie restriction is a consistent extender of longevity 
in worms, flies and mice. The non-additive effects of 
DN p53 and CR argue that p53 signaling and calorie 
restriction are operating in the same pathway or 
affecting the same pathway.   In worms and flies, the 
pathway most consistently associated with longevity 
effects has been the insulin signaling pathway [18].   C. 
elegans and Drosophila mutations in insulin signaling 
pathway members that result in reduced insulin 
signaling often increase longevity and enhance stress 
resistance, probably in part through enhanced dFoxO 
activity [19].  The effects of calorie restriction 
phenocopy those observed in insulin signaling mutants, 
and in flies the affected pathways may overlap.  An 
important advance by the Helfand laboratory was the 
recent demonstration that specific expression of the DN 
Dmp53 transgene in the 14 neurons of the brain that 
produce insulin-like peptides extends lifespan to a 
similar extent as pan-neuronal expression [20].   The 
primary effect of DN Dmp53 in the insulin-producing 
neurons was on reducing production of insulin-like 
peptide 2 (dILP2), while other dILPs remained 
unaffected.  It was demonstrated that reduction of 
dILP2 production was sufficient to inhibit downstream 
insulin signaling, as evidenced by reduced PI-3 kinase 
function in fat bodies of both larval and adult flies.   
Moreover, increased dFoxO nuclear accumulation was 
observed in fat body cells, a key downstream readout 
for attenuated insulin signaling, as increased nuclear 
FoxO is associated with increased stress resistance [19].   
Thus, alterations in p53 signaling in a specific subset of 
secretory neurons were shown to cause major effects on 
insulin signaling pathways in critical target organs such 
as the fat body. 
 
The most recent extension of the Helfand laboratory 
findings are described in this issue [4].   Here, they used 
an inducible GeneSwitch System to temporally 
manipulate expression of the DN Dmp53 transgene.     
Turning on expression of the DN Dmp53 construct at 
10 and 20 days of age in adult Drosophila brains led to 
29% and 12% longer life spans, respectively, compared 
to control flies.   While less than the 47% longevity 
extension observed in flies with constitutive lifelong 
DN Dmp53 expression, it demonstrates that the 
transgene longevity extension is not solely due to 
positive embryonic or early life effects.  The reverse 
experiment of turning off DN Dmp53 expression also 
reduced lifespan extension proportionate to the age of 
turnoff.   
 
The earlier interactions of calorie restriction and DN 
Dmp53 longevity effects were further examined by 
testing interactions of DN Dmp53 and dSir2 
overexpression.   Overexpression of the histone deace-
tylase Sir2 has been associated with increased lifespan 
in yeast, worms, and flies [21].  Moreover, it is 
generally believed that CR acts in part through Sir2 
activation, since Sir2 overexpression and CR longevity 
extension effects are not additive in flies [22].   Here, 
the authors showed that Sir2 overexpressing DN 
Dmp53 flies showed the same longevity as Sir2 
overexpressing flies, indicating no additive effects of 
the two alleles and that they were likely interacting in 
the same pathway relating to CR.  This result was 
confirmed by treament of control flies and DN Dmp53 
flies with resveratrol, a molecular activator of Sir2 that 
has been shown to extend lifespan in yeast, worms, and 
flies.  No significant difference in fly lifespan extension 
was observed among DN Dmp53 flies, resveratrol 
treated control flies, and resveratrol treated DN Dmp53 
flies, suggesting that CR, dSir2 and DN Dmp53 act 
through similar pathways of longevity extension.  
  
The pathway interactions of dSir2 and Dmp53 were 
confirmed at the biochemical level by showing through 
co-immunoprecipitation experiments in fly head lysates 
that Dmp53 and Sir2 physically interact with each 
other.  In addition, purified recombinant dSir2 protein 
deacetylated acetylated peptides corresponding to 
known sites of Dmp53 acetylation in an NAD-
dependent manner.  Co-transfection of wildtype Dmp53 
with a p53 luciferase reporter in Drosophila cells in 
culture resulted in transcriptional activation of the 
reporter that could be suppressed by adding increasing 
doses of the Sir2 activator resveratrol.   Thus, dSir2 was 
shown directly to be a potent inhibitor of Dmp53 
activity.   
 
The experiments described above have facilitated the 
generation of a mechanistic model for how calorie 
restriction activates downstream pathways important in 
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ry has postulated that calorie restriction acts in part 
through activation of dSir2 that in turn suppresses 
Dmp53 in the insulin-producing cells of the brain [20].  
Dmp53 suppression results in reduced production of at 
least one critical insulin-like peptide (dILP2) by the 
insulin-producing cells.  The reduced dILP production 
may regulate a number of downstream targets in the 
insulin signaling pathway, particularly in the fat body.  
Some of these targets, such as dFoxO, 4E-BP, and TOR 
have been shown to play roles in lifespan control in 
model organisms.   
 
The key contribution of the series of Drosophila p53 
papers from the Helfand laboratory is the placement of 
p53 as a key mediator of downstream CR signaling 
effects, in part through its effects on insulin signaling 
pathways. If confirmed by further studies, it will solidify 
a role for p53 as a longevity regulating gene. As always, 
exciting results such as these raise a number of new 
questions that beg to be addressed.   For example, how 
does Dmp53 regulate dILP2 expression to effect 
downstream insulin signaling pathway effects? Are the 
DN Dmp53 effects solely through Dmp53 or are there 
other interaction targets?  Which of the downstream 
insulin signaling pathway targets mediate the lifespan 
extension effects of activated dSir2 and suppressed 
Dmp53?  The authors allude to CR effects that are dSir2 
and Dmp53 independent.  What are these and are they 
also insulin signaling independent?   Does this model 
have applicability to mammalian systems?  In mice, 
where the effects of Sir2 homologues on longevity are 
less clear and where adult tissue stem cells are believed 
to be an important component of aging, different 
pathways or cell types may be associated with CR-
induced longevity effects.   Unraveling these pathways 
in various model systems should provide profound new 
insights into the genetics and biology of aging and 
longevity.  
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